Torray LLC boosted its position in Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) by 15.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,487 shares of the biotechnology company’s stock after buying an additional 2,323 shares during the period. Torray LLC’s holdings in Blueprint Medicines were worth $1,152,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently bought and sold shares of the company. Raymond James & Associates boosted its position in Blueprint Medicines by 18.6% in the 1st quarter. Raymond James & Associates now owns 31,565 shares of the biotechnology company’s stock worth $2,016,000 after purchasing an additional 4,945 shares in the last quarter. US Bancorp DE lifted its position in shares of Blueprint Medicines by 11.4% during the 1st quarter. US Bancorp DE now owns 7,234 shares of the biotechnology company’s stock valued at $463,000 after buying an additional 743 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of Blueprint Medicines by 53.9% during the 1st quarter. MetLife Investment Management LLC now owns 31,782 shares of the biotechnology company’s stock valued at $2,030,000 after buying an additional 11,131 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Blueprint Medicines by 1.5% during the 1st quarter. Rhumbline Advisers now owns 63,434 shares of the biotechnology company’s stock valued at $4,052,000 after buying an additional 924 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of Blueprint Medicines by 0.9% during the 1st quarter. BlackRock Inc. now owns 5,383,138 shares of the biotechnology company’s stock valued at $343,876,000 after buying an additional 46,264 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on BPMC shares. SVB Leerink reduced their price objective on Blueprint Medicines from $57.00 to $52.00 and set a “market perform” rating for the company in a research note on Wednesday, November 2nd. The Goldman Sachs Group cut their target price on Blueprint Medicines from $143.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, November 3rd. Morgan Stanley cut their target price on Blueprint Medicines from $80.00 to $75.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 2nd. Oppenheimer downgraded Blueprint Medicines from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 2nd. Finally, Jefferies Financial Group cut their price objective on Blueprint Medicines from $84.00 to $80.00 in a research report on Wednesday, November 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Blueprint Medicines currently has a consensus rating of “Moderate Buy” and an average price target of $80.00.
Insiders Place Their Bets
In other news, Director Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction on Monday, December 5th. The stock was sold at an average price of $50.09, for a total value of $1,001,800.00. Following the sale, the director now directly owns 183,243 shares in the company, valued at $9,178,641.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Blueprint Medicines news, CEO Kate Haviland bought 1,100 shares of the company’s stock in a transaction that occurred on Thursday, November 3rd. The stock was purchased at an average cost of $43.98 per share, for a total transaction of $48,378.00. Following the completion of the purchase, the chief executive officer now owns 92,281 shares of the company’s stock, valued at approximately $4,058,518.38. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction on Monday, December 5th. The shares were sold at an average price of $50.09, for a total value of $1,001,800.00. Following the completion of the transaction, the director now owns 183,243 shares of the company’s stock, valued at $9,178,641.87. The disclosure for this sale can be found here. 3.42% of the stock is owned by company insiders.
Blueprint Medicines Trading Down 1.8 %
Shares of Blueprint Medicines stock traded down $0.82 during trading on Monday, reaching $45.87. The company’s stock had a trading volume of 40,467 shares, compared to its average volume of 456,926. The company has a quick ratio of 6.79, a current ratio of 6.99 and a debt-to-equity ratio of 0.19. Blueprint Medicines Co. has a 12-month low of $40.78 and a 12-month high of $85.67. The business has a 50 day moving average price of $45.50 and a 200-day moving average price of $55.18.
Blueprint Medicines (NASDAQ:BPMC – Get Rating) last posted its quarterly earnings results on Tuesday, November 1st. The biotechnology company reported ($2.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.51) by $0.28. The firm had revenue of $65.98 million for the quarter, compared to the consensus estimate of $43.49 million. Blueprint Medicines had a negative return on equity of 56.45% and a negative net margin of 263.54%. Equities analysts predict that Blueprint Medicines Co. will post -9.38 EPS for the current fiscal year.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.